Lifeboat Foundation

Continue reading “Regenerage — SMX Radio — The Net of Regenerative Medicine — Bioquark” »

And, so far, they’re just fine. America needs a sober debate about the pros and cons of Crispr instead of a paranoid ban on the technology.

Imagine one drug that can target and kill malignant cells for some patients with many types of cancer. A new drug called Vitrakvi (larotrectinib), now approved by the U.S. Food and Drug Administration, shows promise of doing just that for both adults and children with a variety of sometimes rare cancers that share one specific genetic mutation.

The mutation, called a TRK fusion, occurs when one of three NTRK genes becomes mistakenly connected to an unrelated gene and ignites uncontrolled growth. By solely targeting this mutation, the drug is designed to turn off growth signaling with a minimum of other toxicities.

According to the drug manufacturer, Loxo Oncology, this specific mutation can occur in a small subset of various adult and pediatric solid tumors ranging from cancers of the appendix, bile ducts, breast, lung, pancreas and thyroid to melanoma, GIST and various sarcomas.

Continue reading “FDA Approves Drug That Targets Key Genetic Driver of Cancer” »

Neoliberalism slows down evolution! Just kidding…or am I? 🧐😁🤣🙈.

Like other organisms, bacteria constantly have to fight to survive in hostile living conditions. Together with colleagues in Finland, researchers at the Max Planck Institute for Evolutionary Biology in Plön have discovered that bacteria adapt to their environment more slowly and less efficiently as soon as they are exposed to two stress factors rather than one. This is due to mutations in different genes. The slower rate of evolution led to smaller population sizes. This means that evolution can take divergent paths if an organism is exposed to several stress factors.

Bacteria rarely live alone; they are usually part of a community of species that is exposed to various stress factors. They can often react to these factors by adapting to new environmental conditions with astonishing speed. Antibiotics that enter soil and water via waste water and accumulate there in low concentrations can trigger the evolution of resistance in bacteria – even though these concentrations are so low that they inhibit bacterial growth only slightly or not at all. However, bacteria do not only have to fight antibiotics; they also have to deal with predators. This is why they often grow in large colonies that cannot be consumed by predatory organisms.

Continue reading “Double the stress slows down evolution” »

Continue reading “Bioquark — Electroceuticals — Real Bodies” »

https://paper.li/e-1437691924#/&h=AT3mdHzXuCejMgVQDYy6JiVw58…e-BeRlnE2g

“Our world is changing so fast… this year we have sessions on artificial intelligence, genetics and what the future holds for our planet. There is a new term now — cli-fi. We have a beautiful session on cli-fi, on what would happen if bees disappear.

”I feel at this moment in our country it is very very important to give impetus to empirical thinking,” the author of ”Paro: Dreams of Passion” said.

Continue reading “12th Jaipur Literature Festival: AI, cli-fi, genetics sessions on line-up” »

A team of doctors in Brazil have announced a medical first that could someday help countless women unable to have children because of a damaged or absent uterus. In a case report published Tuesday in the Lancet, they claim to have successfully helped a woman give birth using a transplanted uterus from a deceased donor.

According to the report, the team performed the operation on an unnamed 32-year-old woman in a Brazilian hospital in September 2016. The woman had been born with a rare genetic condition that left her without a uterus, known as Mayer-Rokitansky-Küster-Hauser syndrome, but she was otherwise healthy. The donor was a 45-year-old woman who had suddenly died of stroke; she had had three successful pregnancies delivered vaginally in the past.

• The FDA on Monday approved a new cancer treatment in an unconventional way: not by tumor type, but rather by the genetic mutation the drug targets.
• The drug, Vitrakvi, was developed by Loxo Oncology in partnership with pharma giant Bayer.
• It’s only the second time the FDA has approved a cancer drug’s use based on a certain mutation rather than a particular tumor type.

The Food and Drug Administration on Monday took an unconventional approach to approving a new cancer drug.

The drug, Vitrakvi, was developed by Loxo Oncology. It’s the company’s first drug to get approved.

A blood test can detect cancer within just 10 minutes, scientists have found, raising hopes that hard-to-spot diseases could be picked up early when treatment is most effective.

Currently doctors use symptoms and a raft of tests and biopsies to determine if cancer is present which can sometimes take months.

The new method from the University of Queensland looks for differences in the genetic code of cancerous and healthy cells.

Continue reading “Blood test to detect cancer within just 10 minutes developed by scientists” »